ATH 20.0% 0.4¢ alterity therapeutics limited

Deferiprone can protect mitochondrial injury, page-2

  1. 1,560 Posts.
    lightbulb Created with Sketch. 2
    Are you expecting that Prana would ever have any interest in preventing thromboemboli related to thalassemia thereby wasting their assets even more? It's difficult to understand how PD or movement disorders or whatever is left in Prana's library would be pushed aside to start with another brand new diagnosis. It won't happen, as so many hopeful concepts that are brought to attention here by someone else's abstracts do not happen.

    This is the issue of the day/month/year: We now know thatPBT434 will not enter a Phase I clinical trial this year. Maybe this time Prana is following FDA's trial recommendations before jumping into a clinical trial and then years later finding themselves unable to complete it. I can't think of any other reason. Can anyone else?
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.4¢
Change
-0.001(20.0%)
Mkt cap ! $20.98M
Open High Low Value Volume
0.4¢ 0.4¢ 0.4¢ $298 74.4K

Buyers (Bids)

No. Vol. Price($)
55 69476657 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 20550793 12
View Market Depth
Last trade - 13.22pm 05/06/2024 (20 minute delay) ?
Last
0.4¢
  Change
-0.001 ( 11.1 %)
Open High Low Volume
0.4¢ 0.4¢ 0.4¢ 100000
Last updated 11.49am 05/06/2024 ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.